Carlos Salcido

Scotiabank Concacaf Champions League: All Eyes on C.D. Guadalajara

The New York Red Bulls immediately turned all attention to the Scotiabank Concacaf Champions League matchup against C.D. Guadalajara.

Following New York's MLS match against Orlando City SC, all eyes turned to Chivas.

“My emphasis in the locker room was 'OK, some good, some bad, but right now this trip is not about one game,'" Marsch said. "We have to start looking forward to Wednesday right now and we’re all excited for the opportunity to go to Guadalajara and really put things on the line."

The Red Bulls and Chivas face off in Leg 1 of the Champions League Semis on Wednesday, April 4, at 10 p.m. ET. Leg 2 will take place on April 10 at 8 p.m. ET in Red Bull Arena.

Tickets for the match are on sale now. Fans can buy tickets online at newyorkredbulls.com/tickets or by calling 1-877-727-6223 between the hours of 10 a.m. and 5 p.m. ET. (Tickets to Red Bulls vs. Guadalajara are available as part of a three-match plan, including two MLS matches at Red Bull Arena. Tickets can be included for games against Carlos Vela’s Los Angeles Football Club and David Villa’s New York City FC, among others.)

"What a great challenge that will be," Marsch said. "A lot of respect for the job that [Matias] Almeyda has done with Chivas, they’re a really good team and, man, that is going to be an incredible challenge.”

Chivas qualified for the 2018 Champions League edition after becoming the Liga MX 2017 Clausura champions, winning their 12th league title on an 4-3 aggregate score over Tigres UANL.

As of March 31, Chivas is 12th (out of 18 clubs) in Liga MX, with 15 points through 13 matches played (3-6-4), with a -3 goal differential.

Chivas have had a strong Concacaf campaign so far, knocking-out MLS side Seattle Sounders in the Quarterfinals and boasting an impressing +9 goal differential.

Chivas recently visited Red Bull Arena, as the Liga MX side took on Atletico Nacional de Medellin to meet in "SuperCopa de Campeones" on September 3, 2017.


Topics: